How Long Does Retatrutide Stay in Your System?

Think of a mug of coffee cooling on your desk. It loses heat fastest in the first minutes, then slower and slower as it creeps toward room temperature, because it sheds the same fraction of its remaining warmth in each interval. Retatrutide leaves your blood the same way: the same fraction of whatever is left disappears every 6 days, so the drop is steep in week one and a slow fade after that.

Literally stated: in the phase 1b multiple-ascending-dose trial, retatrutide's pharmacokinetics were dose proportional and its half-life was approximately 6 days (Urva et al., Lancet, 2022, PMID 36354040). Dose proportional means a 12 mg dose starts at three times the blood level of a 4 mg dose but falls at the same rate. The half-life does not change with the dose; only the starting height does.

That rate explains why a 72-hour late dose barely matters while a 14-day gap does. Six days is also the longest half-life of the three weekly incretins: tirzepatide's is about 5 days (Furihata et al., Diabetes Obes Metab, 2022, PMID 34647404) and semaglutide's is about 7 days according to its prescribing information. Run any of them through the peptide half-life tracker to see your own curve.

Retatrutide is an investigational compound. It has no FDA approval, no prescribing label, and no official washout guidance; every practical rule below is derived from its trial pharmacology or borrowed from the labels of tirzepatide and semaglutide, and this page says which is which.

Weekly dosing with a 6-day half-life means each injection lands on top of 45% of the previous one. The drug stacks until the amount you inject equals the amount you clear in a week. At that point your blood level sits about 1.8 times higher than it did after the first dose.

This is why the phase 2 obesity trial escalated every 4 weeks rather than every week: a dose has to reach its plateau before anyone can judge it, and gastrointestinal events in that trial were dose related and most frequent during escalation (Jastreboff et al., N Engl J Med, 2023, PMID 37366315). Jumping a step before week 4 means stacking a new dose on a plateau you never reached. The weekly volumes for each step are in the retatrutide dosage calculator, and the escalation-week side effect map in the retatrutide nausea guide.

The same arithmetic runs in reverse when you stop. Someone who quits after 16 weeks at steady state starts the washout from a level 1.8 times higher than a single dose, so in absolute terms they carry more drug on day 14 than a first-week user carried on day 7. The percentages in the washout table still apply; the starting height is just taller.

Pharmacology treats a drug as cleared after 5 half-lives, when about 3% remains. For retatrutide that is day 30. The table below assumes a user who has been dosing weekly long enough to reach steady state and gives the percentage of the level present on the day of the last injection.

Two things stand out. First, a one-week "break" removes barely half the drug, which is why skipping a single dose feels like a lower dose rather than a stop. Second, the tail is long: 9% at three weeks is still a pharmacologically active amount for a compound whose trial doses ranged from 1 mg to 12 mg.

Body weight, kidney function and liver function shift these numbers by hours, not weeks. Peptides of this class are broken down by proteolytic cleavage of the backbone and beta-oxidation of the fatty-acid side chain, a process that is not confined to any single organ; that is how semaglutide, the closest studied analogue, was shown to clear in humans (Jensen et al., Eur J Pharm Sci, 2017, PMID 28323117). The comparison columns are built from the 5-day and 7-day figures explained in how long tirzepatide stays in your system and how long semaglutide stays in your system.

The molecule and its effects run on different clocks. Blood levels follow the table above; what you feel lags behind it in one direction and runs ahead of it in another.

Appetite and gut effects fade first. Retatrutide delays gastric emptying, and the delay is largest after the first dose and weakens with repeated dosing (Urva et al., Diabetes Obes Metab, 2023, PMID 37311727). Users report hunger returning between day 7 and day 14 after the last dose, while the level is dropping from 45% to 20%. Nausea and loose stools, if you had them, are usually gone inside that same window; the timeline for the latter is in how long retatrutide diarrhea lasts.

Blood sugar drifts back over weeks 2 to 4. In the phase 1b trial the glucose-lowering effect was measured at week 12 of continuous dosing and scaled with dose (Urva et al., Lancet, 2022, PMID 36354040). As the level crosses 20% and then 9%, fasting glucose climbs toward baseline. Anyone with type 2 diabetes who stops should have a plan with their prescriber for that window, because no insulin or metformin adjustment happens on its own.

Weight effect outlasts the drug. In the first-in-human study, a single dose reduced body weight for up to 43 days, which is 7 half-lives (Coskun et al., Cell Metab, 2022, PMID 35985340). The weight comes back after that, and retatrutide has no withdrawal data of its own, so the proxies are its cousins. One year after stopping tirzepatide, participants in SURMOUNT-4 regained 14% of body weight against a 5.5% further loss in those who continued (Aronne et al., JAMA, 2024, PMID 38078870). One year after stopping semaglutide, STEP 1 participants had regained two-thirds of what they lost (Wilding et al., Diabetes Obes Metab, 2022, PMID 35441470). Expect the retatrutide curve to look at least as steep, since its 24% weight loss at 48 weeks in phase 2 (Jastreboff et al., N Engl J Med, 2023, PMID 37366315) leaves more to regain. The head-to-head numbers are in retatrutide vs Zepbound.

The washout curve answers both the "I forgot" question and the "I am switching" question, because both come down to how much retatrutide is still there when the next drug goes in.

Scenario 1, the early switch. You take 12 mg of retatrutide on Friday, decide on Monday to move to tirzepatide, and inject 10 mg of it that evening. Monday is day 3, so 71% of a steady-state 12 mg exposure is still on board, and you have added a full-strength dual agonist on top. The combined incretin load for that week is roughly 1.7 times what your gut is trained for, which is the exposure of a skipped escalation step. Expect vomiting and a day in bed. Fix: wait until the day the next retatrutide dose was due, then start the new drug one or two steps below your target, using the tirzepatide dosage calculator for the units.

Scenario 2, the "it must be gone" restart. You stop for 10 days, assume the drug is out, and restart at your full 12 mg. On day 10 about 31% remains, and tolerance to nausea has partly unwound. You get a 12 mg peak on top of a third of a dose, with a gut that has forgotten the last step. Fix: one step down for one to two weeks, then climb back.

The reverse switch, with its overlap math and starting doses, is in switching from tirzepatide to retatrutide. The principle is identical in both directions: the molecule that is leaving still counts, and semaglutide at a 7-day half-life leaves even slower than retatrutide does.

Surgery. The concern is delayed gastric emptying: food still in the stomach under anesthesia can be inhaled into the lungs. The 2024 multisociety guidance from the anesthesiology, gastroenterology and bariatric surgery societies moved away from blanket holding of GLP-1 receptor agonists and toward a 24-hour liquid diet before the procedure for patients at elevated risk of retained stomach contents, with holding reserved for case-by-case decisions (Kindel et al., Surg Obes Relat Dis, 2024, PMID 39482213). That guidance was written for approved drugs; retatrutide was not studied. Tell the anesthesia team the date of your last dose and the dose, because holding one weekly injection leaves 45% of the drug on board and holding two leaves 20%. A full washout for an elective procedure is 30 days.

Pregnancy. There are no human pregnancy data for retatrutide. The Wegovy label instructs stopping semaglutide at least 2 months before a planned pregnancy (FDA, Wegovy prescribing information, 2021, label PDF), and 2 months covers more than 9 retatrutide half-lives. Treat that as the floor. The class-level reasoning and the tirzepatide label language are in tirzepatide and pregnancy.

Alcohol. No interaction study exists for retatrutide and alcohol. The pharmacology is simple: as long as the drug is present, gastric emptying is slowed, alcohol sits in the stomach longer, and reduced food intake leaves less to buffer it. The gut effect weakens along the same curve as appetite, so a drink at day 14 lands on a very different stomach than a drink at day 3. The class-by-class rules are in can you drink alcohol on peptides.

Retatrutide does not appear on any standard drug screen. Employment panels of 5, 10 or 12 substances look for amphetamines, opioids, cannabinoids, cocaine, benzodiazepines and similar classes, using immunoassays that have no antibody for a 39-amino-acid incretin analogue. It cannot cause a false positive for any of them. The sport and employment detail is in do peptides show up on drug tests.

Detection in a laboratory is a different matter. The phase 1b trial quantified plasma retatrutide with a validated research assay through 12 weeks of dosing (Urva et al., Lancet, 2022, PMID 36354040), so a liquid chromatography mass spectrometry method built for the molecule can find it for as long as the washout curve says it is there, which is 4 to 6 weeks. No commercial clinical laboratory offers that test to patients as of October 2026.

What routine blood work does show is the drug's footprint. Fasting glucose, HbA1c, lipids and liver enzymes reflect retatrutide's effect until it has cleared. If a prescriber wants a true off-drug baseline, draw it at least 30 days after the last injection, and remember that HbA1c averages the previous 2 to 3 months regardless.

Treating one skipped week as a reset. 45% of the drug is still present at day 7. Restarting at full dose is fine; restarting at a higher step because "the slate is clean" stacks on top of what is left. Fix: a 7-day gap changes nothing about the dose.

Switching drugs on the wrong day. Starting tirzepatide or semaglutide 2 or 3 days after the last retatrutide dose adds a full dose to a 70% residue. Fix: the first dose of the new drug goes in on the day the next retatrutide dose was due.

Expecting the weight to hold. The single-dose weight effect lasts to day 43, then the comparator data say the regain runs for a year. Fix: decide what replaces the drug before the last injection, not after the hunger returns.

Assuming the drug tests clean because it tests clean. It passes every employment panel and still shows up on a research assay for 6 weeks. Fix: the honest answer in any disclosure is the date of the last dose.